Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)

Analysts updated ratings for healthcare companies. TD Cowen maintained a Buy rating on TransMedics Group (TMDX) with a $120 target. Regeneron (REGN) was kept at Hold by Leerink Partners. Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a $100 target. All have consensus ratings and price targets.

Original reporting
Published Oct 3, 2026, 1:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 4:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS) — source image
Decision brief

The 30-second read

$TMDXBullishLow
01

Why it matters

Analyst maintenance with target adjustments offers modest directional cues but lacks strong catalyst.

02

Market read

Provides modest guidance for investors; limited immediate trading impact.

03

What to watch

Upcoming earnings releases could override current analyst targets.

Relevance 4/10Novelty 3/10Timing: today

Background

The article aggregates analyst rating updates for three healthcare companies, providing new price targets but no rating changes.

Company-level read

Ticker impact

$TMDXBullishMedium confidence
Context

Analyst Josh Jennings maintained a Buy rating and set a $120 price target for TransMedics Group.

Expected impact

potential modest upside as investors price in higher target

Evidence & confidence

Rating unchanged but target raised suggests confidence in upside.

$REGNNeutralMedium confidence
Context

Analyst David Risinger maintained a Hold rating and RBC Capital kept a Hold with a $737 price target for Regeneron.

Expected impact

likely limited pressure as market sees no change

Evidence & confidence

No rating upgrade or target lift, so price action expected to be muted.

$TARSBullishMedium confidence
Context

Oppenheimer analyst Mazahir Alimohamed maintained a Buy rating and set a $100 price target for Tarsus Pharmaceuticals.

Expected impact

possible slight upside as target exceeds current price

Evidence & confidence

Target increase signals confidence, but rating unchanged.

Market effects

Analyst coverage may slightly lift healthcare sector sentiment.

U.S. market focus; limited regional effect.

Minimal global impact.

Counterpoint

Ratings unchanged; investors may wait for earnings before acting.

Key entities

  • TransMedics Group

    Medical device company

  • Regeneron

    Biopharmaceutical company

  • Tarsus Pharmaceuticals

    Biopharma focused on rare diseases

Related articles

MedAI 8/10

Profits jump 20% at Irish arm of US biotech Regeneron

Regeneron's Irish arm saw a 20% profit increase to $4.91B in 2025, with revenues up 3% to $12.53B. The company paid $716.6M in taxes and $5.3B in dividends. Key drugs Dupixent, Eylea HD, and Libtayo showed strong sales growth. Manufacturing was briefly disrupted due to repairs.

$REGNMed

European Commission approves flexible dosing for Regeneron’s Libtayo

Regeneron Pharmaceuticals (NASDAQ:REGN) received European Commission approval for a flexible dosing schedule for Libtayo (cemiplimab) across six cancer indications. The new regimen allows a 700 mg dose every six weeks after initial treatment, and reduced infusion times. The approval is based on clinical data and modeling. A U.S. review is ongoing, with a decision expected in March 2027.

$REGNMedAI 8/10

Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial

Regeneron's Phase 2 trial for baloncibart (REGN7544) in POTS patients showed significant heart rate reduction at day 8, with the 450-mg dose maintaining benefits at day 29. The company plans to initiate Phase 3 trials in early 2025. According to Regeneron, the drug was generally well-tolerated, and improvements in physical functioning were observed in the higher dose group.